Insight into the metabolic mechanism of Diterpene Ginkgolides on antidepressant effects for attenuating behavioural deficits compared with venlafaxine

Shunjie Bai1,2,3,4, Xiaodong Zhang2,3,6, Zhi Chen1,2,3,4, Wei Wang1,2,3, Qingchuan Hu2,3,4, Zihong Liang2,3,5, Peng Shen2,3,6, Siwen Gui2,3, Li Zeng2,3,6, Zhao Liu2,3,6, Jianjun Chen2,3, Xiongfei Xie2,7, Hua Huang2,3,8, Yu Han2,3,6, Haiyang Wang2,3 & Peng Xie1,2,3,4,6

Depression is a severe and chronic mental disorder, affecting about 322 million individuals worldwide. A recent study showed that diterpene ginkgolides (DG) have antidepressant-like effects on baseline behaviours in mice. Here, we examined the effects of DG and venlafaxine (VLX) in a chronic social defeat stress model of depression. Both DG and VLX attenuated stress-induced social deficits, despair behaviour and exploratory behaviour. To elucidate the metabolic changes underlying the antidepressive effects of DG and VLX, we investigated candidate functional pathways in the prefrontal cortex using a GC-MS-based metabolomics approach. Metabolic functions and pathways analysis revealed that DG and VLX affect protein biosynthesis and nucleotide metabolism to enhance cell proliferation, with DG having a weaker impact than VLX. Glutamate and aspartate metabolism played important roles in the antidepressant effects of DG and VLX. Tyrosine degradation and cell-to-cell signaling and interaction helped discriminate the two antidepressants. L-glutamic acid was negatively correlated, while hypoxanthine was positively correlated, with the social interaction ratio. Understanding the metabolic changes produced by DG and VLX should provide insight into the mechanisms of action of these drugs and aid in the development of novel therapies for depression.
Indeed, a recent study by our group showed that DG has antidepressant-like effects on baseline behaviours in mice. Major depressive disorder is characterized by a chronically dysregulated stress response, and stress has been shown to be a major factor contributing to the development of depression. Therefore, it is necessary to evaluate the effect of DG in a rodent model of depression. The antidepressive effects of venlafaxine (dual reuptake inhibitor of serotonin and norepinephrine) has been shown previously in rodents by our group as well as investigators at other research institutes. Additionally, venlafaxine has been found to exhibit antidepressant activities on typical depression-like behaviours, social avoidance, and anxiety-like behaviours induced by chronic social defeat stress (CSDS) after repeated administration. However, the functional and molecular bases of venlafaxine's antidepressive action in the CSDS model have not been fully clarified. Unbiased overall metabolic profiling may shed new light on the molecular mechanisms targeted by both established and experimental pharmacotherapies, thereby facilitating the development of novel antidepressant treatments that target defined metabolic pathways.

Identifying the brain regions that are functionally affected by antidepressants is necessary for understanding the mechanisms of action of these drugs. The prefrontal cortex (PFC) is a critical neuroanatomical hub that controls motivated behaviours in mammals. Structural, functional and metabolic changes in the PFC are key features of rodent models of depression, and accordingly, it has been the focus of studies on the molecular pathogenesis of the disease. Furthermore, the PFC is not only altered in depressed patients and stressed animals, but is also affected by antidepressants.

Here, we compared the effects of DG and VLX in mice subjected to CSDS, an ethologically validated model of chronic stress and depression. We examined whether administration of DG and VLX could modulate stress-induced behavioural deficits. To elucidate the metabolite changes that may underlie the pharmacological effects of DG and VLX, we investigated candidate functional pathways in the PFC using a metabolomics approach based on GC-MS technology. Investigating the role of DG and VLX in the PFC may offer important novel mechanistic insight into their therapeutic actions and facilitate the development of novel antidepressant drugs.

Results
CSDS induced behavioural deficits. Schedule of the experimental approach is shown in Fig. 1. In accordance with previous studies, mice subjected to 10-day CSDS exhibited sociability deficits. The social interaction (SI) behavioural test was used to evaluate the susceptible (SI ratio < 1) and resilient (SI ratio > 1) phenotypes of defeated mice. As the track (Fig. 2A) and the time in the interaction zone (Fig. 2B) indicated, the susceptible mice spent less time in the interaction zone when a CD1 mouse, "a novel aggressor mouse", was present than when the CD1 mouse was absent. The SI ratio was lower in susceptible mice than in the control and resilient groups (Fig. 2C). 31 (77.5%) out of a total of 40 defeated mice showed susceptible or depressed behavior, and 6 mice (15.0%) showed resilient behavior, according to their SI ratio. 3 mice (7.5%) were excluded from the study because of physical wounding. Only 31 susceptible mice among the 40 defeated mice were used for all further experiments. The susceptible mice were randomly divided into vehicle-treated group (DEP, n = 10), DG-treated group (n = 11) and VLX-treated group (n = 10).

DG and VLX reverse specific stress-induced behavioural deficits. In our previous study, we found that two weeks of treatment with DG produced antidepressant-like effects. In the present study, the SI test was carried out after treatment for 2, 4 and 6 weeks. Until week 6, VLX and DG-treated depressed mice exhibited a higher SI ratio compared with vehicle-treated (DEP) mice (Fig. 3A), indicating an improvement of stress-induced social deficits. However, the DEP group still exhibited pronounced avoidance of the interaction zone. The sucrose preference test (SPT) is a reward-based test, used as an indicator of anhedonia. We previously demonstrated that susceptible mice subjected to CSDS exhibit decreased sucrose preference. This reduced preference for sucrose was not abrogated by treatment with antidepressants (Fig. 3B). The immobility time of the DG group was significantly less than that of DEP group in the FST (Fig. 3C). However, only a tendency for a reduction of the immobility time was shown in the tail suspension test (TST) (Fig. 3D), indicating a partial antidepressant effect of DG on despair behavior. These results suggest that chronic DG and VLX treatments have antidepressant effects in the CSDS model.
Effects of DG and VLX on exploration, locomotion, anxiety and memory behaviours. CSDS also induces anxiety-like behaviour and deficits in exploration\textsuperscript{33,34}. In the open field test (OFT), DG and VLX increased rearing behaviour (Fig. 4A), indicating an amelioration of the exploration deficits. Overall, there was no main effect of treatment on locomotion or time spent in the centre of the open field (Fig. 4B,C). This suggests that DG and VLX have no effect on locomotor activity or anxiety-like behaviour. The elevated plus maze (EPM) is another widely used anxiety paradigm. However, there was no significant difference in this test either, indicating no anxiolytic-like effect of DG or VLX administration (Fig. 4D,E). The Y-maze is a hippocampus-dependent spatial working memory task. There was no significant difference in the percentage of spontaneous alternations (Fig. 4F), indicating DG and VLX might have no influence on spatial memory.

OPLS-DA model of GC-MS metabolomic analysis. In the PCA score plots (Supplemental Figure S2), the $R^2_X$ values were 0.73, indicating the presence of distinct metabolic profile patterns that can be attributed to the specific effects of DG and VLX treatment. These differences could be attributed to changes in levels of metabolites. Then we used the metabolites from the pairwise groups (11 DG mice vs. 10 DEP mice; 10 VLX mice vs. 10 DEP mice, and 11 DG mice vs. 10 DEP mice) to build OPLS-DA models. The pairwise OPLS–DA score plots demonstrated clear discriminations between the DG and DEP groups ($R^2_X = 0.712, R^2_Y = 0.955, Q^2 = 0.857$; Fig. 5A), the VLX and DEP groups ($R^2_X = 0.47, R^2_Y = 0.767, Q^2 = 0.537$; Fig. 5B), and the DG and VLX groups ($R^2_X = 0.649, R^2_Y = 0.895, Q^2 = 0.579$; Fig. 5C). Furthermore, the results of 200-iteration permutation test showed that there were no overfitting, and the models were valid and not overfit (Fig. 5D–F).

Differential metabolites. A total of 19 differential metabolites (VIP > 1.0 and $P < 0.05$) were identified between the DG and DEP groups (Fig. 6A,B; Supplemental Table S1). Compared with the DEP group, 11 metabolites were upregulated in the DG group, and 8 metabolites were downregulated in the DG group compared with the DEP group. 30 differential metabolites (VIP > 1.0 and $P < 0.05$) responsible for distinguishing VLX-treated mice from the vehicle treated mice were identified (Fig. 6A,C; Supplemental Table S2). Compared with the DEP
group, 18 metabolites were upregulated in the VLX group, and 12 metabolites were downregulated in the VLX group relative to the DEP group. Relative to the DEP group, the changes of 15 metabolites in the DG group were same as those in the VLX group; 4 metabolites were specific for DG, attributable to the antidepressant effect, and 15 metabolites were specific for VLX. These results indicate that DG and VLX might exert antidepressive effects through both common and unique molecular pathways. We also compared the differential metabolites between the DG group and the VLX group. Compared with the VLX group, 9 metabolites were upregulated and 8 metabolites were downregulated in the DG group (Supplemental Table S3).

Ingenuity pathways analysis (IPA) of differential metabolites. To understand the molecular pathways and biological functional roles of the differential metabolites, they were mapped into the IPA knowledgebase. The differential metabolites in DG-treated mice were involved in the following top 5 canonical pathways: tRNA charging, purine nucleotides degradation II (aerobic), asparagine biosynthesis I, tyrosine degradation I, and superpathway of citrulline metabolism. The differential metabolites in the VLX-treated mice were involved in the following top 5 canonical pathways: tRNA charging, superpathway of citrulline metabolism, asparagine biosynthesis I, purine nucleotides degradation II (aerobic), and l-glutamine biosynthesis II (tRNA-dependent) (Fig. 7). The predicted biological functions of the DG-related differential metabolites were significantly involved in the “proliferation of cells” (z-score = 2.528) and the inhibition of the “uptake of l-alanine” (z-score = −2.000) (Fig. 8A). The VLX-related differential metabolites were involved in these two predicted biological functions as well (z-score = 2.867 and −2.000, respectively). In addition, VLX was also involved in the “generation of cells” (z-score = −2.213) and in the inhibition of the “uptake of l-amino acid” (z-score = −2.433) (Fig. 8B). Furthermore, DG’s functional impact in the “growth of organism” (z-score = −2.639) was weaker than VLX (Supplemental Figure S4).

IPA network analysis uses the proprietary ingenuity knowledgebase, and constructs networks of altered molecules which are not limited by canonical pathway boundaries. One DG-related network was constructed (shown in Supplementary Figure S5): “cellular compromise, lipid metabolism, small molecule biochemistry”. Two VLX-related networks were constructed (shown in Supplementary Figures S6 and S7): “amino acid metabolism, small molecule biochemistry, cellular compromise” and “energy production, molecular transport, nucleic acid metabolism”.

Enrichment analysis and pathway analysis on MetaboAnalyst. MetaboAnalyst was used to identify altered metabolic pathways and functional roles based on the KEGG metabolic library. According to the following criteria: false discovery rate (FDR) < 0.05 and impact value > 0, the metabolomic alterations induced by DG
were enriched in the function of “protein biosynthesis” (Fig. 9A), and the pathway of “phenylalanine, tyrosine and tryptophan biosynthesis” (Fig. 9B). In comparison, the metabolomic changes induced by VLX were enriched in the function of “protein biosynthesis, urea cycle and beta-alanine metabolism” (Fig. 9C), and the pathway of “phenylalanine, tyrosine and tryptophan biosynthesis, D-glutamine and D-glutamate metabolism, alanine, aspartate and glutamate metabolism, beta-alanine metabolism, pantothenate and CoA biosynthesis, pyrimidine metabolism and arginine and proline metabolism” (Fig. 9D). Additionally, compared with VLX, the metabolomic alterations produced by DG were enriched in the function of “protein biosynthesis”, and the pathway of “alanine, aspartate and glutamate metabolism” (Supplementary Figure S7). Based on the functional roles and pathways of all differential metabolites identified by this analysis, a schematic model depicting the potentially altered metabolic pathways was prepared (Fig. 10).

Correlations between the SI ratio and metabolites. Pearson’s correlative analysis of all the differential metabolites (altered by DG and VLX) and the SI ratios revealed potential relationships between metabolites and SI ratios. Only L-glutamic acid and hypoxanthine showed a significant correlation with the SI ratio (Fig. 11). L-glutamic acid was negatively correlated with the SI ratio ($r = -0.454$, $P = 0.010$), however hypoxanthine was positively correlated with the SI ratio ($r = 0.522$, $P = 0.003$).

Discussion
Depression is a complex and heterogeneous disorder and a major contributor to the global burden of disease, and our group has focused on this disease for many years$^{3,5,16-37}$. The majority of recent studies on antidepressants have focused on tricyclic antidepressants and selective serotonin reuptake inhibitors. However, most of these drugs are characterized by low rates of response and severe adverse reactions. A recent study by our group showed that DG has antidepressant-like effects on baseline behaviours in the mouse$^{14}$, suggesting that this alternative medicine might have therapeutic potential for treating depression.

In the present study, using a validated model of CSDS$^{32,38}$, we demonstrate, for the first time, that DG ameliorates behavioural deficits caused by chronic exposure to CSDS. Both DG and VLX attenuated CSDS-induced behavioural deficits, including the changes in sociability and vertical exploration behaviour. Notably, DG also diminished despair behaviour.

Following CSDS, 77.5% of the defeated mice showed apparent social avoidance, characteristic of susceptible or depressed individuals. Susceptible individuals have been proved to display typical behavioural deficits, including social avoidance, anxiety-like behaviour, despair behaviour and anhedonia$^{33,38}$. In this study, only the susceptible mice were used to screen for antidepressant drugs in further experiments. Even after six weeks, the susceptible mice (DEP group) still showed social deficits (SI ratio < 1; Fig. 3A), indicating high validity of the
CSDS model. VLX is a clinically common antidepressant, but there is only a few definitive evidences that it attenuates CSDS-induced social deficits. Herein, we both tested the antidepressant effects of DG and VLX in the susceptible mice after CSDS.

Our previous study revealed that 2 weeks of DG and VLX treatment led to antidepressant-like effects in mice. However, in the present study, we found no differences in social behaviour (typical depressive behaviour associated with the CSDS model) among the three groups after 2 weeks of treatment. In view of the administration methods described by two independent studies were entirely consistent. The reason why the drugs have no antidepressant effect may be that this study is based on the CSDS model. Similarly, Venzela et al. (2012) also demonstrated that venlafaxine showed antidepressant-like activity in the depressed mice after 30 days of treatment. Therefore, model differences should be taken into account when attempting to replicate such results. After 6 weeks of chronic treatment with DG or VLX, the social deficits were significantly attenuated. It suggested that DG and VLX began to play a significant antidepressant effect after 6 weeks. In this case, we also assessed other depression-like behaviours. In the SPT, DG and VLX did not affect the hedonic response. In the FST and TST, DG decreased the immobility time in the FST, indicating that it impacts partial despair behaviour. In addition, DG and VLX induced more frequent rearings in the OFT, indicating a greater exploratory behaviour. However, neither DG nor VLX had an anxiolytic effect in the OFT or EPM. Furthermore, neither of these drugs influenced memory function in susceptible mice in the Y-maze test.

The PFC is an important brain centre that controls stress responses and regulates susceptibility and resilience after CSDS. We used the high-resolution and reliable GC-MS-based metabolomics approach to study the mechanisms of action of DG and VLX in the PFC of mice. We identified 19 and 30 differential metabolites that definitively discriminated mice in the DG-treated and VLX-treated groups, respectively, including 15 common differential metabolites showing the same trend (Fig. 6). Despite the commonalities, the two groups were clearly distinguishable (Fig. 5C,F), with 17 differential metabolites between them (Supplementary Table S1). This finding suggests that while both DG and VLX could attenuate stress-induced behavioural deficits, their molecular mechanisms of action differ substantially.

To provide further insight into the underlying antidepressive mechanisms, the significantly differential metabolites were analyzed using the IPA knowledgebase to identify their biochemical functions and pathways. This analysis revealed that "tRNA charging" was the top canonical pathway for both DG and VLX. tRNA charging plays an important role in the expression of genes, consistent with the "protein biosynthesis" result obtained with MetaboAnalyst (Fig. 9A,B). This suggests that both DG and VLX affect the biosynthesis of proteins. Interestingly, among all metabolites (L-glutamic acid, L-tyrosine, L-phenylalanine, L-alanine, L-proline, L-threonine,
L-asparagine, L-isoleucine, L-histidine, L-lysine, L-aspartic acid, L-arginine, L-cysteine, L-glutamine, L-leucine, L-methionine, L-valine, L-tryptophan, D-serine) involved in “protein biosynthesis”, only L-glutamic acid was downregulated in both the DG and VLX groups; the remaining metabolites showed upregulation or no change. Based on these results, we speculate that DG and VLX exert their antidepressive effects, at least in part, by enhancing protein biosynthesis. Another important canonical pathway was “purine nucleotides degradation”, which includes phosphate, adenosine 5’-monophosphate, inosinic acid, inosine and hypoxanthine (Fig. 10). This pathway and pyridine metabolism (Fig. 9D) are both nucleotide metabolism pathways. From the schematic diagram (Fig. 10), we can see that upstream metabolites were downregulated, while downstream metabolites were upregulated, indicating that DG and VLX enhance nucleotide degradation. Nucleotide degradation is an importance source of raw materials for the synthesis of nucleic acids and for enhancing pentose phosphate metabolism. Protein biosynthesis and nucleotide metabolism are the two most important requirements for the proliferation of cells, and thus likely accounting for the enhanced cell proliferation in this study. Furthermore, compared with VLX, the impact of DG on “growth of organism” (Supplemental Figure S4) and “protein biosynthesis” (Supplemental Figure S9) was weaker. Among the differential metabolites involved in these functions,

Figure 6. (A) Correlation network between the differential metabolites and DG or VLX. Red-coloured boxes indicate upregulation in the DG or VLX group compared with DEP, while green-coloured boxes indicate downregulation in the DG or VLX group, compared with DEP. The line width represents the fold changes of differential metabolites. The line width represents the VIP scores of the differential metabolites. (B) Heat map the differential metabolites in the comparison of the DG and DEP groups. (C) Heat map of differential metabolites in the comparison of the VLX and DEP groups. DG, diterpene ginkgolides; VLX, venlafaxine.
hypoxanthine, which belongs to nucleotide metabolism, showed a significant positive correlation with the SI ratio (Fig. 10). It is worth noting that the upregulation of hypoxanthine in both the DG and VLX groups is predicted to enhance the proliferation of cells, as shown by IPA in Fig. 8.

Another three canonical pathways—“superpathway of citrulline metabolism”, “asparagine biosynthesis I” and “L-glutamine biosynthesis II” —which belong to “alanine, aspartate and glutamate metabolism” were also influenced by DG or VLX treatment. The schematic diagram shows that aspartate metabolism and glutamate metabolism were significantly affected pathways, which include 9 differential metabolites. These two pathways are associated with neurotransmitter metabolism. L-glutamic acid, a significant excitatory neurotransmitter in the mammalian CNS, was decreased both in DG and VLX-treated mice. Previous studies by others and our research group have revealed that glutamate metabolism played a significant role in depression33, 39, 41, 42. Lower L-glutamic acid levels are detected in the PFC of depression-resistant mice 33, and the glutamatergic system has been effectively used as a target for the treatment of depression43, 44. In our study, the changes in glutamate metabolism indicate that DG and VLX might exert their antidepressive effects by reducing glutamate excitotoxicity. Aspartate metabolism also helped discriminate the metabolic profiles of DG and VLX-treated mice from that of controls. The biosynthesis of asparagine is essential for the development and function of the brain45. Previous studies have suggested that asparagine levels may predict the response to antidepressant treatment19, 46. In addition, the “superpathway of citrulline metabolism”, including (including adenosine 5’-monophosphate, L-aspartic acid, L-glutamic acid, L-glutamine, L-proline, phosphate and fumaric acid) is also mainly involved in aspartate and glutamate metabolism. L-asparagine is biosynthesized from L-aspartic acid by asparagine synthetase using

Figure 7. Top canonical pathways enriched in the PFC for comparisons of the DG vs. DEP and the VLX vs. DEP groups. DEP, vehicle-treated mice; DG, diterpene ginkgolides-treated mice; VLX, venlafaxine-treated mice.

Figure 8. Predicted biological functions (z-score > 2 or z-score < -2) associated with DG (A) or VLX (B) treatment identified by ingenuity pathways analysis.
L-glutamine as an amino group donor. The results are in line with the assumption that the decline in glutamate metabolism strengthens aspartate metabolism. Additionally, among the differential metabolites, L-glutamic acid showed a significant negative correlation with the SI ratio (Fig. 10). This suggests that the downregulation of L-glutamic acid in both the DG and VLX groups might play an important role in mediating the antidepressive effects of these drugs.

The pathway “tyrosine degradation I” was significantly affected in DG-treated mice, but not in VLX-treated mice. The upregulation of L-tyrosine might enhance its degradation. L-tyrosine is the precursor of dopamine. Consistent with this finding, our lab’s previous study showed that fluoxetine upregulates tyrosine in astrocytes19, and that tyrosine is downregulated in the brain of a rat model of depression41. Therefore, the observed tyrosine upregulation in DG-treated mice suggests that DG therapy might attenuate despair behaviours through a tyrosine-related mechanism.

The initial IPA results showed that “amino acid metabolism, small molecule biochemistry, cell-to-cell signaling and interaction” (Supplemental Figure S8) play key roles in discriminating the two antidepressants. However, both amino acid metabolism and small molecule biochemistry were influenced by DG and VLX. Therefore cell-to-cell signaling and interaction are critical for discriminating the two antidepressants. The results from the IPA database analysis predicted that ERK1/2, akt, Mapk, EGFR and NTS, which have been reported as highly correlated with the pathogenesis of depression, are hub genes that discriminate the effects of DG and VLX on the PFC in mice (Supplemental Figure S8).
Finally, to better clarify the antidepressant effect of DG, we compared the significant metabolites in this study with those documented in our previous report (Supplemental Figure S10). Since the models and brain regions used were different, there were only three common metabolites (pyroglutamic acid, asparagine, and inosine).

Figure 10. A simplified schematic diagram of the metabolic changes induced by DG and VLX treatment. Red-coloured boxes indicate upregulation, yellow-coloured boxes indicate no significant change, while green-coloured boxes indicate downregulation in the DG or VLX group when compared with DEP group respectively. DG, diterpene ginkgolides; VLX, venlafaxine. TCA, tricarboxylic acid; ADP, adenosine diphosphate; ATP, adenosine triphosphate.

Figure 11. Correlation of differential metabolites with the social interaction ratio (n = 31). *P = 0.010 (L-glutamine vs. social interaction ratio); **P = 0.003 (hypoxathine vs. social interaction ratio), by Pearson’s test.

Finally, to better clarify the antidepressant effect of DG, we compared the significant metabolites in this study with those documented in our previous report (Supplemental Figure S10). Since the models and brain regions used were different, there were only three common metabolites (pyroglutamic acid, asparagine, and inosine).
Pyroglutamic acid is a downstream metabolite of glutathione, which serves as an antioxidant. The downregulation of pyroglutamic acid reflects a lower degradation of glutathione. Evidence has shown that depressed patients and animals subjected to stress have an excessive oxidation status. Therefore, DG may induce an antidepressant effect through its antioxidant properties. Asparagine is a neurotransmitter-related amino acid. The inconsistency regarding asparagine changes in the two studies may be due to differences in asparagine levels in distinct brain regions. Accumulating evidence has suggested that inosine has promising antidepressant effects in animal models of depression. Muto et al. revealed that inosine may produce antidepressant-like effects through neuroprotection in CSDS mice, and Kaster et al. also reported that inosine may possess antidepressant-like effects in the FST and TST in mice through the activation of adenosine receptors. Consequently, it is an interesting finding that DG could display antidepressant effects through upregulating inosine level.

There are several limitations of our study that should be acknowledged. First, the number of samples in this study was relatively small. A study with a larger sample size and using a targeted metabolomics approach is required for better assessing the effects of DG and VLX on depression-like behaviours. Second, the comparisons in this study were based on depressed mice. An additional comparison between naive and depressed mice might help clarify the antidepressive mechanisms of action of DG and VLX. Finally, administering ginkgolides A, B, C and K individually might help distinguish the antidepressive effects of these component ginkgolides.

**Conclusion**

In conclusion, both DG and VLX effectively attenuate stress-induced social deficits, despair behaviour and exploratory behaviour in mice. Comparative metabolomic profiling of the PFC revealed that DG and VLX have both common and distinct antidepressive molecular mechanisms of action. Both antidepressants influence protein biosynthesis and nucleotide metabolism to enhance cell proliferation, but DG has a weaker impact on these processes than VLX. Glutamate and aspartate metabolism might play an important role in the antidepressive effects of DG and VLX. Tyrosine degradation and cell-to-cell signalling and interaction play key roles in discriminating the two antidepressants. Moreover, interestingly, L-glutamic acid was negatively correlated with the SI ratio, while hypoxanthine was positively correlated with the SI ratio. Investigating the metabolic changes produced by DG and VLX in the PFC should provide important insight into the cell and molecular changes underlying the therapeutic actions of these medicines, as well as help advance antidepressant drug discovery efforts.

**Materials and Methods**

**Animals and ethics statement.** Male C57BL/6 mice (aged approximately 6–8 weeks and weighing 20–25 g) and male CD-1 (ICR) mice (aged approximately 18–20 weeks and weighing 35–40 g) were obtained from the laboratory animal centre of Chongqing Medical University (Chongqing, China). Mice were housed individually in standard polypropylene cages with wood shavings, under a 12-h dark/light cycle (lights on at 8:00 am) and a temperature (23 ± 2°C) and relative humidity controlled environment. All animal experimentation procedures were performed according to the recommendations of the Guide for the Care and Use of Laboratory Animals, and were approved by the Ethics Committee of Chongqing Medical University (Permit number: 20120126).

**CSDS and drug treatments.** The CSDS procedure was performed as previously reported. During the 10-day defeat period, the C57BL/6 mouse was introduced to a novel aggressive resident CD-1 mouse for 10 min every day. Immediately after the social defeat session, the resident CD-1 mouse and the C57BL/6 intruder mouse were housed in one half of the cage which were separated by a perforated transparent Plexiglas divider for continued sensory contact. Then, 24 h after the last stress session, the C57BL/6 mouse was housed individually, and the SI test was performed to identify subgroups of mice that were susceptible or resilient to CSDS. This was accomplished by placing mice in an open field box (44 cm × 44 cm × 30 cm) with an empty perforated plastic box (10 cm × 7 cm × 18 cm) located at one end. The movement of the mice was videotaped for 2.5 min, followed by 2.5 min in the presence of an unfamiliar CD-1 mouse confined in the perforated plastic box. The movements were quantified by an animal movement analysis system (SMART, Panlab SL, Barcelona, Spain). The time spent in the interaction zone (defined as the 8-cm-wide area surrounding the perforated plastic box) was recorded. The SI ratio = time spent in an interaction zone with a CD-1 mouse/time spent in an interaction zone without a CD-1 mouse. An SI ratio of 1 was set as the cut-off. Mice with scores <1 were defined as susceptible to social defeat stress and those with scores >1 were defined as resilient. Only susceptible mice were used in the subsequent experiments.

After the CSDS procedure, the susceptible mice were randomly divided into the following three groups: (1) depressed group (DEP; 0.9% NaCl solution; n = 10), (2) DG group (12.18 mg/kg; Diterpene Ginkgolides Meglumine Injection, provided by Jiangsu Kanion Pharmaceutical Co., Ltd, diluted in 0.9% NaCl solution; n = 11) and (3) VLX group (16 mg/kg VLX, diluted in 0.9% NaCl solution, n = 11). Mice were given intraperitoneal injections daily in a volume of 200 μl. The doses were based on our previous study.

**Behavioural testing.** After drug treatment, a series of behavioural studies were performed during the daytime (lights-on period) under conditions of dim light and low noise. All behavioural tests were videotaped and quantified by an animal movement analysis system (SMART, Panlab SL, Barcelona, Spain). The behavioural tests used are well established. The experimental timeline and study design are shown in Fig. 1.

*SPT:* The SPT was performed to evaluate the anhedonic response after treatment. After 24 h deprivation of water and food, the two-bottle preference test was conducted which all mice had access to water and 1% sucrose water for 24 h. Sucrose preference = sucrose intake/(sucrose intake + water intake) × 100%.

*OFT:* Mice were placed individually in the centre of an open field box (44 cm × 44 cm × 30 cm) and allowed 5.5 min to move freely. After 0.5 min of adaptation, the distance travelled and the duration spent in the centre...
were analyzed during a period of 5 min using the SMART system. Rearings were scored in a blind manner by an experimenter. After each test, the field was cleaned with a 75% ethanol solution.

**EPM:** The EPM consisted of 4 arms (30 cm long and 6 cm wide), with two open arms (no side or end walls) and two closed arms (15-cm-high side walls and 15-cm-high end walls). A central 6 cm × 6 cm square platform allowed access to all arms. Mice were placed in the central square, and after 0.5 min of adaptation, the distance travelled, the number of entries and the duration in each arm during a 5-min period were analyzed using the SMART system. The degree of anxiety was assessed by calculating the time or percentage of time spent in the open arms.

**TST:** Mice were individually hung on a hook by their tails using a small piece of adhesive tape (2 cm from the tip of the tail). Every test session lasted 6 min, and the last 5 min were scored by SMART to assess immobility. Animals were considered to be immobile only when they remained hung on the hooks passively and were completely motionless.

**Y-maze:** The Y-maze apparatus consisted of three arms intersecting at 120° (45 cm long, 10 cm wide and 29 cm high). Mice were placed at the end of one arm and allowed to freely explore the three arms for 8 min. The sequence and the total number of arms entered was noted. Percentage of spontaneous alternation was defined as [(number of alternations)/(total number of arm entries − 2)] × 100%.

**FST:** The mice were placed individually in a clear Plexiglas cylinder (30 cm in height, 15 cm in diameter) filled with water (25 ± 1°C) to a height of 15 cm. Test sessions lasted for 6 min, and the last 5 min were scored by SMART to assess immobility. Animals were considered to be immobile only when there were only occasional slight movements (required to keep the head out of the water).

**GC-MS metabolomics analysis.** The procedure for GC-MS metabolomics was conducted in accordance with our previous study. The day after the completion of the behavioral tests, the mice were anesthetized with chloral hydrate and decapitated, and the whole brains were removed. The PFC was separated from the brain, weighed, rapidly frozen with liquid nitrogen, and stored at −80°C until analysis.

Prior to GC-MS metabolomics analysis, each 20 mg piece of PFC was ground with 400 µL of a methanol and water (4:1) solution containing L-2-chlorophenylalanine (0.075 mg/mL, internal standard) using a tissue homogenizer. The mixture was sonicated and centrifuged, and the liquid supernatant was gathered and lyophilized. Then, the dried extract was derivatized into its methoxime derivatives by a reaction with methoxamine hydrochloride in pyridine (15 mg/ml). Subsequently, the solution was derivatized with BSTFA (1% TMCS) and n-hexane at 70°C for 60 min, and placed at room temperature for 30 min before analysis.

Metabolic profiling of the PFC in a discovery set based on non-targeted analysis was performed using the Agilent GC system 7890 A equipped with a 5975 C mass-selective detector system. Typical GC settings and MS parameters were used. Briefly, the temperatures of the injector, the EI iron source and the quadrupole rods were set at 280°C, 230°C and 150°C, respectively. High-purity helium carrier gas flowed at a steady rate of 6 mL/min. A 0.5-µL aliquot of each sample was used for metabolite separation. Column temperature was initially kept at 70°C for 2 min, increased to 160°C at a rate of 6°C/min, then raised to 240°C at a rate of 10°C/min, and finally raised to 300°C at a rate of 20°C/min. This temperature was maintained for 6 min. MS spectra were acquired from m/z 50 to 600.

The chromatographic peaks in the total ion current (TIC) chromatograms represent corresponding metabolites, and their relative concentrations can be detected using the peak area normalization method. In the present study, the TIC from the three group PFC samples revealed strong signals for analysis, large peak capacity and good retention time reproducibility (Supplemental Figure S1). 646 individual peaks were detected in each group. These peaks were annotated by comparing the accurate mass (m/z) and retention time (RT) from the National Institute of Standards and Technology online databases. The relative intensities of these metabolites were used in the subsequent multivariate statistical analysis.

**Statistical analysis.** All data from the behavioural tests were expressed as means ± SEM. The time in the interaction zone (SI test) data were analysed using two-tailed t-tests for comparisons between target and no target, and other data were analyzed by one-way analysis of variance (ANOVA), followed by the post hoc least significant difference test or Dunnett’s test, depending on the homogeneity of variances, with repeated measures as indicated. Significance was denoted at a P-value < 0.05. The SPSS 21.0 software package (IBM, Armonk, NY, USA) was used for all statistical tests. The statistical analysis of the correlation between significant metabolites and the SI score was performed using Pearson’s test. For plotting all data, Graphpad Prism 7.0 (GraphPad Software, Inc, USA) was used.

GC–MS-based metabolomics data were converted into a NetCDF file format using TagFinder. The peak indexes (RT-m/z), sample names and normalized peak intensities were imported into SIMCA 14.1 (MKS Umetrics, AB). Multivariate statistical analyses, including principal component analysis (PCA) and pair-wise orthogonal projections to latent structures discriminant analyses (OPLS-DA) with Pareto scaling spectral data was performed to visually discriminate samples in the CON, DG and VLX groups. R²Y and Q² were used to quantify the quality of the model. Significant metabolites were indicated by VIP > 1 (variable importance in the projection value) and a P-value < 0.05 (obtained from two-tailed Student’s t-test). Cytoscape software 3.4.0 was used to build the correlation network between these differential metabolites and DG treatment or VLX treatment.

**Metabolic functions and pathways analysis.** The module for metabolite set enrichment analysis (MSEA) and the module for pathway analysis in the MetaboAnalyst 3.0 website was used to identify the metabolic pathways significantly affected by these metabolites. We used MetaboAnalyst to generate a heat map of all the different metabolites. IPA software (Qiagen, Redwood City, CA, USA) was used to analyze the different metabolites to obtain information about predicted molecular pathways and biological functions, as described in
http://www.ingenuity.com. IPA Molecule Activity Predictor was used to predict the activity of molecules highly connected to these networks. The z-score was used to identify significant biological functions and pathways, and a z-score $>|2$ or $<-2$ indicated significance. Moreover, the network score was used to determine the relevance between metabolites and networks.

References

1. Organization, W. H. Depression and other common mental disorders: global health estimates (2017).
2. Zheng, P. et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. *Molecular psychiatry* 21, 786–796, doi:10.1038/mp.2016.44 (2016).
3. consortium, C. Sparse whole-genome sequencing identifies two loci for major depressive disorder. *Nature* 523, 588–591, doi:10.1038/nature14659 (2015).
4. Ren, Q. et al. Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. *Proceedings of the National Academy of Sciences of the United States of America* 113, E1944–1952, doi:10.1073/pnas.1601532113 (2016).
5. Cipriani, A. et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. *The Lancet* doi:10.1016/S0140-6736(16)30385-5 (2016).
6. Zhou, X. et al. Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: A systematic review and network meta-analysis. *World Psychiatry Official Journal of the World Psychiatric Association* 14, 207–222 (2015).
7. Fang, H. et al. Insight into the metabolic mechanism of scoparone on biomarkers for inhibiting Yanghuang syndrome. *Scientific reports* 6, 37519 (2016).
8. Kuele, V. & Efferth, T. Cameroonian medicinal plants: pharmacology and derived natural products. *Front Pharmacol* 1, 123, doi:10.3389/fphar.2010.00123 (2010).
9. Ng, T. B., Liu, F. & Wang, Z. T. Antioxidative activity of natural products from plants. *Mol Med Rep* 6, 368–377 (2000).
10. Kuete, V. & Efferth, T. Cameroonian medicinal plants: pharmacology and derived natural products. *Mol Med Rep* 6, 368–377 (2000).
11. Fang, H. et al. Sparse whole-genome sequencing identifies two loci for major depressive disorder. *Nature* 523, 588–591, doi:10.1038/nature14659 (2015).
12. Oberpichler, H., Sauer, D., Rossberg, C., Mennel, H. D. & Krieglstein, J. PAF antagonist ginkgolide B reduces postischemic neuronal damage in rat brain hippocampus. *Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism* 10, 133–135, doi:10.1038/jcbfm.1990.17 (1990).
13. Liebgott, T. et al. Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion. *Basic Res Cardiol* 95, 368–377 (2000).
14. Liang, Z. et al. GC-MS-Based Metabolomic Study on the Antidepressant-Like Effects of Diterpene Ginkgolides in Mouse Hippocampus. *Behavioural brain research* 314, 116–124 (2016).
15. Autry, A. E. Neurobiology of Chronic Social Defeat Stress: Role of Brain-Derived Neurotrophic Factor Signaling in the Nucleus Accumbens. *Biological psychiatry* 80, e39–40, doi:10.1016/j.biopsych.2016.07.006 (2016).
16. Liang, Z. et al. GC-MS-based metabolic study on the antidepressant-like effects of diterpene ginkgolides in mouse hippocampus. *Behavioural brain research* 314, 116–124, doi:10.1016/j.bbr.2016.08.001 (2016).
17. Venzala, E., Garcia-Garcia, A. L., Elizalde, N., Delagrange, P. & Tordera, R. M. Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors. *Psychopharmacology* 224, 313–325 (2012).
18. Kulkarni, S. K. & Dhir, A. Effect of various classes of antidepressants in behavioral paradigms of despair. *Progress in neuro-psychopharmacology & biological psychiatry* 31, 1248 (2007).
19. Bai, S. et al. 1H NMR-based metabolic profiling reveals the effects of fluoxetine on lipid and amino acid metabolism in astrocytes. *International journal of molecular sciences* 16, 8490–8504, doi:10.3390/ijms16048490 (2015).
20. Zheng, P. et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. *Molecular & Cellular Proteomics* 12, 207–214 (2013).
21. Liu, L. et al. The identification of metabolic disturbances in the prefrontal cortex of the chronic restraint stress rat model of depression. *Behavioural brain research* 305, 148–156 (2016).
22. Chen, G. et al. Amino acid metabolic dysfunction revealed in the prefrontal cortex of a rat model of depression. *Behavioural brain research* 278, 286–292, doi:10.1016/j.bbr.2014.05.027 (2015).
23. Bagot, R. C. et al. Ketamine and Imipramine Reverse Transcriptional Signatures of Susceptibility and Induce Resilience-Specific Gene Expression Profiles. *Biological psychiatry* 81, 285–295, doi:10.1016/j.biopsych.2016.06.012 (2017).
24. Warden, M. R. et al. A prefrontal cortex-brainstem neuronal projection that controls response to behavioural challenge. *Nature* 492, 428–432 (2012).
25. Otis, J. M. et al. Prefrontal cortex output circuits guide reward seeking through divergent cue encoding. *Nature* doi:10.1038/nature21376 (2017).
26. Bagot, R. C. et al. Circuit-wide Transcriptional Profiling Reveals Brain Region-Specific Gene Networks Regulating Depression Susceptibility. *Neuron* 90, 969–983, doi:10.1016/j.neuron.2016.04.015 (2016).
27. Baxter, L. R. Jr. et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. *Archives of general psychiatry* 46, 243–250 (1989).
28. Mayberg, H. S. et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. *Biological psychiatry* 48, 830–843 (2000).
29. Jin, C. et al. Ginsenoside Rg1-induced antidepressant effects in the protection of astrocyte gap junctions within the prefrontal cortex. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* (2016).
30. Aoki-Yoshida, A. et al. Omics Studies of the Murine Intestinal Ecosystem Exposed to Subchronic and Mild Social Stress. *Journal of proteome research* 15, 3126–3138, doi:10.1021/acs.jproteome.6b00262 (2016).
31. Berton, O. et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. *Science* 311, 864–868, doi:10.1126/science.1120972 (2006).
32. Golden, S. A., Covington, H. E. 3rd, Berton, O. & Russo, S. J. A standardized protocol for repeated social defeat stress in mice. *Nature protocols* 6, 1183–1191, doi:10.1038/nprot.2011.361 (2011).
33. Wang, V. et al. Targeted Metabolomic Pathway Analysis and Validation Revealed Glutamatergic Disorder in the Prefrontal Cortex among the Chronic Social Defeat Stress Mouse Model of Depression. *Journal of proteome research* 15, 3784–3792, doi:10.1021/acs. jproteome.6b00577 (2016).
34. Kinsey, S. G., Bailey, M. T., Sheridan, J. F., Padgett, D. A. & Avissur, R. Repeated social defeat causes increased anxiety-like behavior and alters spinophyte function in C57BL/6 and CD-1 mice. *Brain Behavior & Immunity* 21, 458–466 (2007).
35. Mu, J. et al. Neurogenesis and major depression: implications from proteomic analyses of hippocampal proteins in a rat depression model. *Neuroscience letters* 416, 252–256, doi:10.1016/j.neulet.2007.01.067 (2007).
36. Yang, Y. et al. The Extrinsic Coagulation Pathway: a Biomarker for Suicidal Behavior in Major Depressive Disorder. *Scientific reports* 6, 32882, doi:10.1038/srep32882 (2016).
37. Luo, Q. et al. Frequency dependent topological alterations of intrinsic functional connectome in major depressive disorder. *Scientific reports* **5**, 9710, doi:10.1038/srep09710 (2015).

38. Krishnan, V. et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. *Cell* **131**, 391–404, doi:10.1016/j.cell.2007.09.018 (2007).

39. Veenith, P. et al. Dysfunctional glutamatergic and γ-aminobutyric acidergic activities in prefrontal cortex of mice in social defeat model of depression. *Biological psychiatry* **76**, 231–238 (2013).

40. Kumar, S. Prefrontal cortex reactivity underlies trait vulnerability to chronic social defeat stress. *Nature Communications* **5**, 4537–4537 (2014).

41. Shao, W. H. et al. Metabolic identification of molecular changes associated with stress resilience in the chronic mild stress rat model of depression. *Metabolomics* **9**, 433–443 (2013).

42. Ni, Y. et al. Metabolic profiling reveals disorder of amino acid metabolism in four brain regions from a rat model of chronic unpredictable mild stress. *FEBS letters* **582**, 2627–2636, doi:10.1016/j.febslet.2008.06.040 (2008).

43. Mathews, D. C., Henter, I. D. & Zarate, C. A. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. *Drugs* **72**, 1313–1333, doi:10.2165/11633130-000000000-00000 (2012).

44. Maeng, S. & Zarate, C. A. Jr. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. *Current psychiatry reports* **9**, 467–474 (2007).

45. Ruzzo, E. K. et al. Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalophy. *Neuron* **80**, 429–441, doi:10.1016/j.neuron.2013.08.013 (2013).

46. Maes, M., Verkerk, R., Vandoolaeghe, E., Lin, A. & Scharpe, S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. *Acta psychiatraca Scandinavica* **97**, 302–308 (1998).

47. Maes, M., Galecki, P., Chang, Y. S. & Berk, M. A review on the oxidative and nitrosative stress (OXNS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. *Progress in neuro-psychopharmacology & biological psychiatry* **35**, 676–692, doi:10.1016/j.pnpbp.2010.05.004 (2011).

48. Sarandol, A. et al. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative–antioxidative systems. *Human Psychopharmacology: Clinical and Experimental* **22**, 67–73 (2007).

49. Muto, J. et al. Oral administration of inosine produces antidepressant-like effects in mice. *Scientific reports* **4**, 4199, doi:10.1038/srep04199 (2014).

50. Goncalves, F. M. et al. Signaling pathways underlying the antidepressant-like effect of inosine in mice. *Purinergic Signal* **13**, 203–214, doi:10.1007/s11302-016-9551-2 (2017).

51. Kaster, M. P. et al. The antidepressant-like effect of inosine in the FST is associated with both adenosine A1 and A2A receptors. *Purinergic Signal* **9**, 481–486, doi:10.1007/s11302-013-9561-8 (2013).

52. Chen, J. J. et al. Effects of gut microbiota on the microRNA and mRNA expression in the hippocampus of mice. *Behavioural brain research* **322**, 34–41, doi:10.1016/j.bbr.2017.01.021 (2017).

53. Guo, M. et al. Role of the adipsic PPARγ-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors. *Molecular psychiatry* doi:10.1038/mp.2016.225 (2016).

54. Bevilaqua, F. et al. Involvement of the catecholaminergic system on the antidepressant-like effects of Alpinia zerumbet in mice. *Pharmaceuticala biology* **54**, 151–156, doi:10.1016/j.pharmbio.2015.02.0287 (2016).

55. Li, J. et al. Peripheral blood mononuclear cell-based metabolic profiling of a chronic unpredictable mild stress rat model of depression. *Molecular biosystems* **10**, 2994–3001, doi:10.1039/c4mb00388h (2014).

56. Lucdemann, A., Strassburg, K., Erban, A. & Kopka, J. TagFinder for the quantitative analysis of gas chromatography–mass spectrometry (GC-MS)-based metabolite profiling experiments. *Bioinformatics* **24**, 732–737, doi:10.1093/bioinformatics/btm023 (2008).

57. Xia, J. & Wishart, D. S. Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis. *Curr Protoc Bioinformatics* **55**, 14 10 11–14 10 11, doi:10.1002/cpbi.11 (2016).

Acknowledgements

This work was supported by the National Basic Research Program of China (973 Program, Grant no. 2009CB918300), the National Natural Science Foundation of China (Grant No. 81371310 and 81601208), the Natural Science Foundation of Inner Mongolia Autonomous Region of China (Grant No. 2016MS0884), the Foundation Project of the Inner Mongolia Autonomous Region People's Hospital (Grant No. 201551), and the Chongqing Science &Technology Commission (Grant No. csc2014czyjA10102).

Author Contributions

S.B. accomplished the manuscript and figures. X.Z., Z.C. and W.W. analyzed the raw data. Z.L., Q.H., P.S., S.G., L.Z., Z.L., J.C., X.X., H.H., Y.H. and H.W. performed the experiments and improved the language of the manuscript. P.X. conceived the experiments.

Additional Information

Supplementary information accompanies this paper at doi:10.1038/s41598-017-10391-1

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017